ALNYLAM PHARMACEUTICALS, INC. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Alnylam Pharmaceuticals, Inc. on August 4, 2004. The filing serves to announce the company's financial results for the quarter ended June 30, 2004. The detailed results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The filing explicitly states that the full financial data is located in the attached press release (Exhibit 99.1), which is not included in the source text provided.
Material Changes
The filing text does not provide specific details regarding material changes versus the prior comparable period. Investors must refer to the referenced press release for comparative analysis.
Guidance, Outlook, and Risks
The text does not include management commentary, forward-looking guidance, specific risks, or contingencies. It notes that the information in this Form 8-K and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into other filings unless expressly stated.
Key Facts for Investor Verification
- Verify the specific financial figures for the quarter ended June 30, 2004, by reviewing the press release (Exhibit 99.1) referenced in this filing.
- Confirm the legal status of the information, as the filing explicitly disclaims liability under Section 18 of the Exchange Act for the content of the press release.
- Note that the filing was signed by John M. Maraganore, Ph.D., President and Chief Executive Officer.